samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

TP3 Global receives Royal recognition by winning the Queen’s Awards for Enterprise 2018

TP3 Global


Birmingham, UK, 23 April 2018 – TP3 Global, a leading global innovator and provider of thermal protection for temperature sensitive cargo, is pleased to announce it has been awarded the 2018 Queen’s Awards for Enterprise in the International Trade category for its globally-recognised Silverskin™ brand.

The Queen’s Awards for Enterprise are the United Kingdom’s most prominent business awards, which commend enterprise excellence. TP3 Global won the recognition for outstanding growth in overseas sales over the past three years. SilverSkinTM has become a major brand in the market, recognised, approved and used by the leading pharmaceutical companies around the world. TP3 Global has seen rapid growth thanks to a strong focus on providing consistent quality and innovative solutions to a worldwide client base.

Clive Wheeldon, President of TP3 Global, commented: “We are extremely proud to achieve the prestigious Queen’s Award for Enterprise for international trade. Our commitment to providing market-leading products, innovation and high-quality customer service has resulted in working with the industry’s leading pharmaceutical companies.

 “We continue to invest heavily in R&D, global footprint and customer service ensuring we stay at the forefront of the market. We are delighted to see many of the world’s pharmaceutical companies utilise SilverskinTM to maintain the integrity of their products in their supply chain. Our team is very proud to have won a prestigious Queen’s Award that recognises our on-going commitment to innovation and excellence for international trade.”

 The Queen’s Awards for Enterprise first began in 1966. They are awarded to businesses for outstanding achievement in four categories International Trade, Innovation, Sustainable Development and also for Promoting Opportunity (through social mobility).



phone 01962 435006
email lisa@amplify-pr.co.uk
web www.tp3global.com
 
Print this page
Send to a friend
   
spacer
White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

Pharma Packaging and Labelling East Coast 2019

20-21 February 2019, Phildaelphia, USA

Now in its 11th year, Pharma Packaging and Labeling is back to deliver key, actionable insights into very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your packaging and labeling chain with both maximum efficiency and minimal cost.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement